Another Humira Biosimilar Debuts In India
This article was originally published in Scrip
Executive Summary
A second biosimilar version of AbbVie's blockbuster biologic, Humira (adalimumab), has made its debut in India, with Torrent Pharma following Zydus Cadila onto the domestic market with its version.
You may also be interested in...
Hetero Set To Join Indian Humira Biosimilar Line-Up
Hetero’s biosimilar version of AbbVie's Humira (adalimumab) appears on course to a debut in India and is set to follow peers like Zydus Cadila and Torrent, signaling the build-up of more competition for the blockbuster biologic across markets.
Hetero Set To Join Indian Humira Biosimilar Line-Up
Hetero’s biosimilar version of AbbVie's Humira (adalimumab) appears on course to a debut in India and is set to follow peers like Zydus Cadila and Torrent, signaling the build-up of more competition for the blockbuster biologic across markets.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.